The US FDA has approved Waters' at-home cervical cancer screening kit, which is designed to detect all high-risk types of human papillomavirus. The kit can be collected at home and sent to a lab, with results shared with the patient. The company is working with the National Cancer Institute to confirm the accuracy of the home sample collection. It is expected to be available for purchase by prescription and will be covered by private insurance and federal programs.